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 IMT is a common condition in dogs and can be primary or secondary in nature 
 Diagnosis is made by evaluating clinical signs and performing a platelet count 
 Treatment usually includes aggressive immunosuppressive therapy, which 
frequently can be associated with multiple side effects 
 Nursing care plans will incorporate detailed observation records and support 
to monitor and minimize haemorrhage 
 Owner communication and support from the point of diagnosis is vital in the 
longer term after discharge, to ensure compliance and appropriate 
management 
Key Words 
 Canine Immune Mediated Thrombocytopenia 
 Platelet count 
 Veterinary Nursing 
 Immunosuppressive therapy 
Word Count: 3089 
This document is the Accepted Manuscript version of a Published Work that appeared in final form in the 
Veterinary Nurse, copyright © MA Healthcare, after peer review and technical editing by the publisher. To 
access the final edited and published work see https://doi.org/10.12968/vetn.2019.10.5.264 
Canine Immune Mediated Thrombocytopenia  
Abstract 
Immune Mediated Thrombocytopenia (IMT) is a common disease in dogs. Primary 
IMT is idiopathic, while secondary IMT is as a result of another underlying cause. 
Symptoms may include lethargy, anorexia and mild pyrexia, together with a low 
platelet count and associated bleeding disorders. Prognosis is generally positive, but 
reduced with presence of melena or raised blood urea nitrogen. Treatment will include 
some form of immunosuppressive therapy, such as Prednisolone, which can have 
multiple side effects. Nursing the IMT patient will aim at monitoring and reducing 
spontaneous haemorrhage and managing treatment side effects. To ensure owner 
understanding and compliance, it is vital to discuss these side effects and any 
appropriate home adjustments, so an achievable plan can be developed for home 
care. 
Introduction 
The aim of this article is to provide an up to date overview of this disease and highlight 
key aspects of nursing care and owner support. Immune Mediated Thrombocytopenia 
(IMT) is the most common cause of a low platelet count seen in dogs. Destruction of 
the platelets occurs when immunoglobulins attach to the platelet surface, causing 
macrophages to respond and initiate phagocytosis (Harvey, 2011). Primary IMT is 
idiopathic and only diagnosed after the exclusion of the causes of secondary IMT and 
other causes of thrombocytopenia, such as bone marrow disorders. Secondary IMT 
can result from an infectious agent, such as viral, bacterial or parasitic organisms, 
neoplasia or a drug induced aetiology, such as the use of sulpha-based antibiotics 
(Cummings and Rizzo, 2017). Blood transfusion may also induce IMT (Day and Kohn, 
2012).  
Signalment 
This is a common disease and occurs more frequently in dogs than cats. Signalment 
is strongly associated with Primary IMT (Day and Kohn, 2012).  Documented breed 
pre-dispositions include; Cocker Spaniels (Image 1), Miniature and Toy Poodles, 
Golden Retrievers, German Shepherds and Old English Sheep Dogs.  Females are 
twice more likely to be affected than males (O’Marra, Delaforcade and Shaw, 2011). 
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Age of onset reported in the literature ranges from <1 – 14 years, however, the majority 
of cases are reported to with a median age between 4 – 8.1 years (Day and Kohn, 
2012, 2012; O’Marra, Delaforcade and Shaw, 2011; Lewis and Meyers, 1996). 
Image 1: Cocker Spaniel “Bertie”  
(Author’s image) 
 
Symptoms and Diagnosis 
Owners may present their pets with lethargy, weakness, anorexia and mild pyrexia. 
The usual signs of platelet dysfunction may be observed on examination, such as 
bruising of the skin (petechiae or ecchymosis), epistaxis or rhinorrhagia in more severe 
forms, haematuria, gingival or ocular haemorrhages. Up to 50% of cases may present 
with splenomegaly (Harvey, 2011). A normal platelet count can be within the range of 
200-400 109/L (Day and Kohn, 2012). Spontaneous haemorrhage will usually suggest 
a platelet count of less than 30-50 x 109/L. A low platelet count may be the only 
haematological abnormality in primary IMT. However, only 5-15% of IMT cases will be 
idiopathic in origin (Park et al., 2015). When using a commercial haematology machine 
in-house, a blood smear is required for visual analysis, particularly when the result is 
abnormal.  Platelet count results from commercial machines can be unreliable, 
especially if there is platelet clumping or macro-platelets in the sample (Image 2).  
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Image 2: Platelet clump with macro and giant platelets; 
Note some platelets are about the same size as an erythrocyte 
Image courtesy of Dr R.M.Lukacs (TDDS Ltd, VPG Synlab)  
 
Blood smear - production 
Producing a good quality smear requires practice and consistency, which are essential 
for appropriate diagnostic quality. Smears made from a fresh EDTA sample, as soon 
after collection as possible, will result in increased diagnostic quality. Smears 
produced from samples older than 24 hours will frequently show ageing changes that 
often impedes/interferes with the interpretation. After adequate drying, the smear can 
be stained with a commercial stain set such as Rapi-Diff or Diff-Quik. These stains 
should be regularly replaced, rather than just topped up, to reduce artefacts on the 
smear during the staining process. Once stained, smears should be stored at room 
temperature.   
Blood smear – platelet examination 
In dogs, platelets do not have a nucleus and are normally one quarter the size of a red 
blood cell. They have an irregular, circular outline with a pale purple-pink granular 
appearance (Image 3 and 4). When examining the stained and dried smear, first check 
the feathered edge for large clumps of platelets, these can result in a false low reading 
on the haematology machine (Image 3). Then examine the mono-layer, just behind 
the feathered edge using a methodical technique, such as the battlement method. 
Examine 10 separate fields, using this technique and note the number of platelets in 
each field. In a healthy patient, there would typically be 10-30 per oil immersion field 
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(Image 4). Generally, if there are only 2-3 clumps, with a low machine count and no 
other platelets visible (Image 5), it is likely the overall count is low. 
 
Image 3: Platelet clumping in the feathered edge 
Image courtesy of Dr R.M.Lukacs (TDDS Ltd, VPG Synlab)  
Image 4: Blood film with normal density of platelets  
Image courtesy of Dr R.M.Lukacs (TDDS Ltd, VPG Synlab)  
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Image 5: Blood film demonstrating thrombocytopenia 
Image courtesy of Dr R.M.Lukacs (TDDS Ltd, VPG Synlab)  
 
Prognosis  
A recent study of 45 dogs by Simpson, Chapman and Klag, (2018), following cases 
up to one year after diagnosis, stated a mortality rate of 11.9%. They reported 89.6% 
survived to discharge and 31% of those relapsed, within an average of 79 days after 
successful treatment. Short term survival rates are suggested to be 74-97%, with a 
recurrence rate of 26-58% (O’Marra, Delaforcade and Shaw, 2011). Cases presenting 
with melena or raised blood urea nitrogen (BUN) are at greater risk of mortality, with 
only around a 60% survival rate. (Cummings and Rizzo, 2017).  
Treatment 
This will be determined by a multitude of factors, especially when relating to secondary 
IMT, as the underlying cause will require targeted treatment. However, in all cases 
there will need to be a degree of immunosuppression to prevent the destruction of 
platelets by the reticulo-endothelial system. The goal of immunosuppressive therapy 
is to increase the platelet count to >40 x 109/L. The following treatments were reviewed 
by Nakamura, Tompkins and Bianco (2012). 
Corticosteroids 
Commonly Prednisolone is the first line choice, providing a consistent and low cost 
immunosuppressive therapy and should achieve satisfactory increase in platelet 
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counts within 7 days, to >50-100 x 109/L. This will greatly reduce or remove the risk of 
spontaneous haemorrhage.  
Other immunosuppressant therapy 
Alongside corticosteroids, the veterinary surgeon may prescribe a concomitant 
therapy with different classes of immunosuppressive drugs.  This can reduce the dose 
required of corticosteroid and the associated side-effects, although cost may be 
increased. Azathioprine at 2mg/kg/day can be used, but will be of little benefit in acute 
cases as it may take over four weeks to achieve the required response. Cyclosporine 
has demonstrated efficacy in dogs with immune disorders, but the side effects include 
gastro-intestinal (GI) signs, anorexia and weight loss. Mycophenolate mofetil has been 
used with corticosteroids and has shown comparable results when compared with a 
cyclosporine-corticosteroid combination, with less side effects and lower cost, 
therefore this may be an emerging alternative (Cummings and Rizzo, 2017). 
Vincristine 
Traditionally used as chemotherapy for oncology patients, it is known to stimulate the 
production of platelets in healthy dogs, studies have shown it can benefit the recovery 
of patients with acute IMT, with a single dose administered in addition to corticosteroid 
therapy (Park et al., 2015; Rozanski et al., 2002). However, the side effects associated 
with chemotherapy should be carefully considered and discussed with the owner. This 
should include managing urinary and faecal excretion with consideration for owner 
and public safety. In cases that do not respond to traditional therapy (Refractory IMT), 
or those which have intolerance to steroid treatment, vincristine loaded platelet therapy 
may offer an alternative solution. This type of therapy targets the vincristine to the 
antiplatelet antibodies, thus destroying the phagocytic cells that are engulfing the 
platelets (Park et al., 2015). 
Splenectomy   
An alternative treatment option for steroid-refractory or dependent immune 
thrombocytopenia patients includes splenectomy. This option is usually reserved for 
patients that fail to respond well to all other medical therapies. By removing the spleen, 
the primary site for clearance of the platelets is eliminated, this also prevents the 
production of autoantibodies. There is limited research in this field however, survival 
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and remission statistics for patients that require this level of intervention varies greatly 
based on individual status and many require long term medical management (Scuderi 
et al., 2016).  
 
Nursing the IMT patient 
Nursing patients with IMT can be challenging, it is important to consider the care of 
the patient holistically in order to identify deterioration and prevent self-trauma 
(Garland, 2011). The accommodation provided should be suitably padded, ensuring 
comfort and protection from surfaces which may cause localised haemorrhage. The 
environment needs to be quiet and calm to encourage the patient to settle adequately. 
Patients with acute IMT or in crisis will typically be lethargic and depressed, however 
due to the scope in clinical presentation, ages affected and individual tolerance to 
symptoms, this is not always the case (O’Marra, Delaforcade and Shaw, 2011). Some 
dogs can become distressed when in the hospital environment, this can make 
management complicated as high levels of stress and agitation may increase blood 
pressure, heart and respiratory rate and the likely hood of self-inflicted injury (Scotney, 
2013). Nursing interventions to calm the patient including audio enrichment, 
pheromones and boredom breakers could be implicated with positive impact, however 
need to be managed to prevent over stimulation or gum abrasions on toys for example 
(Lloyd, 2017).  
Creating a detailed nursing care plan is vital for the continuous and seamless delivery 
of treatment and review. Patient observations need to be recorded comprehensively 
in order to accurately monitor changes, this includes observations of petechiae to the 
mucosal membranes and pupils. Photographing or drawing the extent of this will allow 
thorough progress reports to be formed, which may impact treatment plans and 
increase communication among the team (Chartier, 2015). Regular urinalysis and 
haematology is also advised including packed cell volume and blood smears to 
evaluate secondary changes post diagnosis as well as monitoring changes to the 
mean platelet volume (Schwartz et al., 2014). Strategic sample site selection can help 
to reduce subcutaneous bleeding. Utilising the peripheral limbs will allow suitable 
pressure to be applied post sampling and inflict less trauma (Herring and McMichael, 
2012). Injections, intravenous fluid therapy and infusions are challenging to manage, 
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where appropriate oral medication should be favoured. If essential, intravenous 
catheters can be used however, require close monitoring and strict hygiene 
management to ensure patency and reduce localised trauma (Swhartz et al., 2014). 
Signs of anaemia, epistaxis and dyspnoea should be monitored closely, (See Images 
6 & 7), as well as increasing haematuria and haemochezia (Viviano, 2013). 
Hypovolemia can be seen in some severe cases, especially where gastrointestinal 
haemorrhaging is present, as this route facilitates large volumes of blood loss. Patients 
experiencing severe haemorrhage can be given platelets either via platelet-rich 
plasma or fresh whole blood transfusions, although this will help prevent loss of life, 
the impact this will have on the platelet count longer term is minimal since they will be 
rapidly destroyed (Nakamura, Tompkins and Bianco, 2012). Alternatively, these 
patients can be provided with crystalloid or colloidal infusions to combat hypovolemia 
and any indication of anaemia can be addressed with packed red blood cell or fresh 
whole blood transfusions (Nakamura, Tompkins and Bianco, 2012).  
There are various side effects associated with some of the primary treatments, many 
of which may be given at an aggressive rate. Commonly, corticosteroids are 
prescribed at high levels to suppress the immune system quickly (Cummings and 
Rizzo, 2017). The rapid onset, which is beneficial to the condition, is associated with 
a change in clinical signs, this includes, but is not limited to; sudden changes of 
behaviour, polydipsia/polyuria, polyphagia and excessive panting. Ensuring the 
patient has access to water and toileting facilities can be time consuming but needs to 
be factored into ward duties. Due to the sudden suppression to the immune system is 
it also advisable to instigate reverse barrier nursing (Wang, Smith and Creevy, 2013). 
Once the patient’s status has stabilised a home care plan should be formulated for 
discharge, this should be considered in conjunction with the owner to ensure a realistic 
plan is agreed.  
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Image 6: Monitoring mucous membranes  Image 7: Regular TPR assessments are essential 
Image courtesy of Millpark Veterinary Centre  Image courtesy of Millpark Veterinary Centre  
 
Owner relationship management  
The process of treating and supporting patients with IMT can be prolonged and costly. 
Factors affecting owner compliance have been studied previously with mixed results, 
the scope of individual clients needs differs greatly and therefore presents an issue 
across the industry (Wareham, Brennan and Dean, 2018). Trust and understanding 
are vital when advising clients on health care, this is especially important when 
considering the long-term administration of pharmaceuticals and care. The methods 
used to communicate this to the client should be well adjusted for their individual 
needs, considering a range of circumstances (Gerrard, 2015).  Ensuring the correct 
support structures are in place to aid owners is essential, practices should strive to 
build a strong rapport with clients and provide suitable information to encourage 
compliance (Best, 2013). The best way to achieve this is to involve them in all 
discussions and reassessments of the patient, including treatment options. Although 
this is time consuming and requires a great deal of sensitivity and interpersonal skills, 
the relationship gained will have long term benefits (Loftus, 2014).  
Before discharging it is beneficial to conduct a consultation to discuss home care See 
Image 8). This should include costs involved with treatment, behavioural changes, 
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managing immune suppression, changes needed to the home and prognosis (Notari, 
Burman and Mills, 2015).  
There are some key elements which can optimise communication, consider;  
 Environment and tone of practitioner 
 Advise the client in advance of the time you will need to discuss their pet, this 
will prevent clients rushing to leave and missing the information  
 Condition specific hand out 
 Individualised plan; owners can be reassured by advice that is specifically for 
their animal, avoid generic discharge sheets 
 Use demonstrations; it is always a good idea to see what method will work for 
the patient so you can give the owner confidence and introduce the patient to 
the new routine. Positive reinforcement is key here for long term medicating.  
Once discharged, a follow up call over the next couple of days is a good way to 
reinforce your support to the client and gain an idea of the patient’s progress. At this 
point any emerging issues can be resolved and you will allow the owner the opportunity 
to ask questions they potentially had not previously considered (Gerrard, 2015). Follow 
up consultations should be arranged with the veterinary surgeons or veterinary nurses-
depending on the context. By utilising a combination of the two, clients can be 









Image 8: Discharge consultation 
(Author’s image) 
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Understanding the side effects 
Owners need to be prepared and take a preventative approach where possible with 
regard to side effects. Some of the most prominent issues that arise from treatment 
include (Cummings and Rizzo, 2017)  
 Skin break down and infection:  High doses of steroids weaken the skin and 
allow bacteria build up. Consider the home environment and exercise areas, 
maintaining hygiene can help to reduce infection risk. Exercise areas may also 
need to be considered as rough terrain or woodland for example may increase 
the instance of small skin abrasions or cuts via bushes and branches thus 
increasing the opportunity of localised skin infection to occur.  
 Polydipsia and polyuria: Can be complex to manage and distressing to all 
parties. Owners need to record their routine in a diary and try various methods 
to control the increased urinary output as this tends to one least favoured side 
effects seen.  
 Polyphagia: Can be managed by increasing food volume and decreasing the 
average calories intake per meal. One of the best ways to meet the mental need 
of the patient is to break down their meals into multiple feeds per day and add 
some form of puzzle to each feeding session. This will prolong the activity, allow 
cognitive engagement and entertain the patient thus calming them overall. It is 
important to remember that although weigh gain can be seen with steroid use, 
high doses often result in muscle and weight loss whilst increasing the 
appearance of a pot belly.   
 Behavioural changes: Can include stress behaviour, panting, change in 
tolerance to other pets and children, possession (food especially) and 
depression. Behavioural changes should be recorded by the owner and used 
to assess the quality of life of the patient whilst considering suitable adjustment 
and counter protocols.  
 Fatigue: Owners should refine the exercise routine of the patient to ensure they 
are not stressed physically. In the early stages of treatment exercise is 
contraindicated in many cases due to the risk of bleeding, exacerbated by high 
blood pressure and physical exuberance.    
 Gastrointestinal signs: Some medications can cause diarrhoea and GI tract 
bleeding, this can be evaluated via faecal analysis. 
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 Pancreatitis: This can be a complex issue thought to be primary with ITP or a 
secondary reaction to inflammation or due to bleeding into the pancreas.  
Managing expectations 
If surgical options are considered, such as splenectomy, it is important for the owner 
to understand the added complications of wound management, as well as the 
increased surgical risk and costs involved. Wound management of 
immunosuppressed patient’s, on pharmaceuticals which inadvertently reduce healing, 
will usually require additional time, monitoring and nursing (Notari, Burman and Mills, 
2015) 
It can be hard to discuss euthanasia, if the treatment is unsuccessful. However, for the 
preparation of the owner and the quality of life for the patient it is good to have a clear 
idea from the beginning, this will enable the client’s expectations to be managed and 
make the welfare of the patient easily placed at the forefront of every decision. When 
tapering down the doses there is potential for both positive and negative results to be 
seen and often a mixture (Simpson, Chapman and Klag, 2018). This can be frustrating 
and upsetting and needs to be managed with care. When there is little to no hope of 
the patient making a full recovery, there needs to be an open discussion about the 
patient’s ongoing quality of life. During this time, the relationship your practice has 
worked so hard to achieve will be put to the test, often rewarding your efforts. Via the 
partnership built with clients the ability to have these discussions can be easier, and 
although the emotional investment has not had the desired outcome, clients should 
feel able to confide in the team you have created (Best, 2013). 
Conclusion  
IMT is a common condition in dogs, which overall has a good recovery rate, although 
this is reduced to 60% if presenting with melena or raised blood urea nitrogen (BUN). 
Nursing care should focus on monitoring and minimizing haemorrhage and incorporate 
detailed planning and recording of the patient’s condition. Treatment and associated 
side effects of steroid therapy can be difficult and distressing for the owner to manage 
after discharge. Therefore, it is vital to establish close support and communication from 
the onset and maintain this during the tapering of therapies. 
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